4//SEC Filing
Mayne Pharma International Pty Ltd 4
Accession 0001144204-18-007440
CIK 0001042418other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 7:47 PM ET
Size
9.5 KB
Accession
0001144204-18-007440
Insider Transaction Report
Form 4
Mayne Pharma International Pty Ltd
10% Owner
Transactions
- Purchase
Common Stock
2017-12-19$162660.00/sh+600,000$97,596,000,000→ 198,106,132 total
Mayne Pharma Ventures Pty Ltd
Director10% Owner
Transactions
- Purchase
Common Stock
2017-12-19$162660.00/sh+600,000$97,596,000,000→ 198,106,132 total
Mayne Pharma Group Ltd
10% Owner
Transactions
- Purchase
Common Stock
2017-12-19$162660.00/sh+600,000$97,596,000,000→ 198,106,132 total
Footnotes (2)
- [F1]On December 19, 2017, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 600,000 shares of Common Stock from Stefan Cross.
- [F2]These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.
Documents
Issuer
HedgePath Pharmaceuticals, Inc.
CIK 0001042418
Entity typeother
IncorporatedAustralia
Related Parties
1- filerCIK 0001611534
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 7:47 PM ET
- Size
- 9.5 KB